<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">JRSM Open</journal-id><journal-id journal-id-type="iso-abbrev">JRSM Open</journal-id><journal-id journal-id-type="publisher-id">SHR</journal-id><journal-id journal-id-type="hwp">spshr</journal-id><journal-title-group><journal-title>JRSM Open</journal-title></journal-title-group><issn pub-type="epub">2054-2704</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25057377</article-id><article-id pub-id-type="pmc">4012670</article-id><article-id pub-id-type="doi">10.1177/2042533313518913</article-id><article-id pub-id-type="publisher-id">10.1177_2042533313518913</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>A randomised controlled trial of topical Kanuka honey for the treatment of psoriasis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fingleton</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1-2042533313518913">1</xref><xref ref-type="corresp" rid="corresp1-2042533313518913"/></contrib><contrib contrib-type="author"><name><surname>Sheahan</surname><given-names>Davitt</given-names></name><xref ref-type="aff" rid="aff2-2042533313518913">2</xref></contrib><contrib contrib-type="author"><name><surname>Corin</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="aff3-2042533313518913">3</xref></contrib><contrib contrib-type="author"><name><surname>Weatherall</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff4-2042533313518913">4</xref></contrib><contrib contrib-type="author"><name><surname>Beasley</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff1-2042533313518913">1</xref><xref ref-type="aff" rid="aff4-2042533313518913">4</xref></contrib></contrib-group><aff id="aff1-2042533313518913"><label>1</label>Medical Research Institute of New Zealand, Wellington, New Zealand</aff><aff id="aff2-2042533313518913"><label>2</label>Papamoa Pines Medical Centre, Tauranga, New Zealand</aff><aff id="aff3-2042533313518913"><label>3</label>Clinical Horizons, Tauranga, New Zealand</aff><aff id="aff4-2042533313518913"><label>4</label>University of Otago Wellington, Wellington, New Zealand</aff><author-notes><corresp id="corresp1-2042533313518913">James Fingleton. Email: <email>james.fingleton@mrinz.ac.nz</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2014</year></pub-date><volume>5</volume><issue>3</issue><elocation-id seq="c">2042533313518913</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder content-type="society">The Royal Society of Medicine</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions></article-meta></front><body><sec id="sec1-2042533313518913"><title>Objectives</title><p>There are anecdotal reports of topical honey being effective in the treatment of psoriasis but no clinical trials as a single agent. One study reported use of a honey, beeswax and olive oil mixture alone and in combination with topical steroids, and suggested that this mixture may be effective for the treatment of atopic dermatitis and psoriasis.<sup><xref rid="bibr1-2042533313518913" ref-type="bibr">1</xref></sup> We report a pilot study of the acceptability and feasibility of topical medical grade Kanuka honey for the treatment of psoriasis.</p></sec><sec id="sec2-2042533313518913"><title>Design</title><p>An open-label single blind randomised controlled trial was conducted. Participants applied medical-grade Kanuka honey (Honeylab, NZ) to a representative lesion on one side and aqueous cream BP to the other, nightly for two weeks. Lesions were covered with a dry non-adherent dressing overnight. Choice of side was randomised by coin toss.</p></sec><sec id="sec3-2042533313518913"><title>Setting</title><p>Two primary care practices in Tauranga, New Zealand.</p></sec><sec id="sec4-2042533313518913"><title>Participants</title><p>There were 15 adult participants with a doctor&#x02019;s diagnosis of psoriasis involving the limbs, with bilateral lesions to allow comparison between treatments. Participants receiving any corticosteroid, or who were allergic to honey, were excluded.</p></sec><sec id="sec5-2042533313518913"><title>Main outcome measures</title><p>Primary outcome measure was the intensity component of the validated Psoriasis Area and Severity Index,<sup><xref rid="bibr2-2042533313518913" ref-type="bibr">2</xref></sup> assessed by a second investigator blinded to treatment allocation. Unblinded secondary outcome measures were participant-rated lesion severity and acceptability of honey therapy, both measured by Visual Analogue Score (VAS). The study was approved by the Multi-Region Ethics Committee of New Zealand (NZ) and written informed consent was obtained from all participants. Analysis was by paired signed rank test for intensity, and paired <italic>t</italic>-tests were used for the comparison of severity.</p></sec><sec sec-type="results" id="sec6-2042533313518913"><title>Results</title><p>All subjects were included in the analysis, mean (SD) age 52.1 (13.6), and the results are shown in <xref ref-type="table" rid="table1-2042533313518913">Table 1</xref>. Blinded investigator-rated lesion intensity decreased with both treatments, with no significant difference between honey and cream after two weeks. The severity VAS scores decreased after two weeks with no difference between treatments. Self-reported adherence was good with 95% of applications completed, and a mean duration of application of over 9&#x02009;h for both honey and aqueous cream. Participants rated honey acceptability highly, mean VAS score 71.1 (27.6). Narrative feedback suggested that Kanuka honey can be applied and removed easily, and that overnight application is practicable. There were no treatment-related adverse events.
<table-wrap id="table1-2042533313518913" position="float"><label>Table 1.</label><caption><p>Comparison of two weeks&#x02019; treatment with honey vs. aqueous cream in psoriasis.</p></caption><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Honey</th><th rowspan="1" colspan="1">Aqueous cream</th><th rowspan="1" colspan="1">Honey minus cream</th><th rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody align="left" valign="top"><tr><td colspan="5" rowspan="1">
<italic>Acceptability</italic>
</td></tr><tr><td rowspan="1" colspan="1">Score (0&#x02013;100)</td><td rowspan="1" colspan="1">71.1 (27.6)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td colspan="5" rowspan="1">
<italic>Clinical outcomes</italic>
</td></tr><tr><td colspan="5" rowspan="1"> Intensity (0&#x02013;12)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V1</td><td rowspan="1" colspan="1">4.2 (1.5)</td><td rowspan="1" colspan="1">4.0 (1.4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V2</td><td rowspan="1" colspan="1">2.9 (1.4)</td><td rowspan="1" colspan="1">3.2 (1.5)</td><td rowspan="1" colspan="1">&#x02212;0.3 (1.2)</td><td rowspan="1" colspan="1">0.61<xref ref-type="table-fn" rid="table-fn2-2042533313518913">*</xref>
</td></tr><tr><td rowspan="1" colspan="1">Change with treatment</td><td rowspan="1" colspan="1">&#x02212;1.3 (1.0)</td><td rowspan="1" colspan="1">&#x02212;0.8 (1.5)</td><td rowspan="1" colspan="1">&#x02212;0.5 (1.5)</td><td rowspan="1" colspan="1">0.25<xref ref-type="table-fn" rid="table-fn2-2042533313518913">*</xref>
</td></tr><tr><td rowspan="1" colspan="1">Severity (0&#x02013;100)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V1</td><td rowspan="1" colspan="1">49.3 (25.9)</td><td rowspan="1" colspan="1">49.1 (23.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V2</td><td rowspan="1" colspan="1">32.1 (27.6)</td><td rowspan="1" colspan="1">36.9 (28.2)</td><td rowspan="1" colspan="1">&#x02212;4.8 (&#x02212;13 to 3.7)<sup><xref ref-type="table-fn" rid="table-fn3-2042533313518913">&#x02020;</xref></sup>
</td><td rowspan="1" colspan="1">0.25<sup><xref ref-type="table-fn" rid="table-fn4-2042533313518913">&#x02021;</xref></sup>
</td></tr><tr><td rowspan="1" colspan="1">Change with treatment</td><td rowspan="1" colspan="1">&#x02212;17.2 (16.8)</td><td rowspan="1" colspan="1">&#x02212;12.2 (10.8)</td><td rowspan="1" colspan="1">&#x02212;5.0 (&#x02212;14.3 to 4.4)<sup><xref ref-type="table-fn" rid="table-fn3-2042533313518913">&#x02020;</xref></sup>
</td><td rowspan="1" colspan="1">0.27<sup><xref ref-type="table-fn" rid="table-fn4-2042533313518913">&#x02021;</xref></sup>
</td></tr><tr><td colspan="5" rowspan="1">
<italic>Adherence</italic>
</td></tr><tr><td rowspan="1" colspan="1">Duration of use (min)</td><td rowspan="1" colspan="1">565.8 (76.7)</td><td rowspan="1" colspan="1">563.0 (76.1)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2042533313518913"><p>Values reported as mean (SD) unless otherwise stated. For Psoriasis Area and Severity Index intensity scores, higher scores represent more severe disease. Acceptability scores range from 0 &#x02018;completely unacceptable&#x02019; to 100 &#x02018;completely acceptable&#x02019;. Severity scores range from 0 &#x02018;mildest possible&#x02019; to 100 &#x02018;Worst possible&#x02019;. V1: Baseline visit 1; V2: Visit 2 after two weeks&#x02019; treatment.</p></fn><fn id="table-fn2-2042533313518913"><label>*</label><p>Signed rank tests.</p></fn><fn id="table-fn3-2042533313518913"><label>&#x02020;</label><p>Mean (95% confidence interval).</p></fn><fn id="table-fn4-2042533313518913"><label>&#x02021;</label><p>Paired <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="conclusions" id="sec7-2042533313518913"><title>Conclusions</title><p>In this pilot single blind randomised controlled trial of topical medical grade Kanuka honey for the treatment of psoriasis, Kanuka honey treatment was found to be both feasible and acceptable. Efficacy was similar to that of the aqueous cream control. Aqueous cream is recommended as a treatment in psoriasis<sup><xref rid="bibr3-2042533313518913" ref-type="bibr">3</xref>,<xref rid="bibr4-2042533313518913" ref-type="bibr">4</xref></sup> and therefore may be seen as an active comparator; however, the efficacy of aqueous cream is significantly less than that of agents such as topical steroids. An important limitation of this study is the small sample size and partial blinding. Complete blinding is not possible due to the physical characteristics of honey. We conclude that topical application of medical grade Kanuka honey is feasible and acceptable to patients. Kanuka honey may have similar efficacy to aqueous cream in the management of psoriasis, but this requires confirmation in a suitably powered study.</p></sec></body><back><sec id="sec8-2042533313518913"><title>Declarations</title><sec id="sec9-2042533313518913"><title>Competing interests</title><p>Dr Shaun Holt, the Medical Director of Honeylab, was previously the Programme Director of Complementary Medicine at the Medical Research Institute of New Zealand.</p></sec><sec id="sec10-2042533313518913"><title>Funding</title><p>The study was sponsored by Honeylab, a manufacturer of medical grade Kanuka honey. The Sponsor had no role in the design, conduct and analysis of the study or the decision to publish.</p></sec><sec id="sec11-2042533313518913"><title>Guarantor</title><p>JF</p></sec><sec id="sec12-2042533313518913"><title>Ethical approval</title><p>The study was approved by the Multi-Region Ethics Committee of New Zealand (NZ), MEC/12/03/022, and written informed consent was obtained from all participants.</p></sec><sec id="sec13-2042533313518913"><title>Contributorship</title><p>JF, MW and RB designed the study with input from DS and AC. JF, DS and AC conducted the study with analysis performed by MW, JF and RB. JF wrote the first draft and all authors revised and approved the final manuscript.</p></sec><sec><title>Acknowledgements</title><p>None</p></sec><sec id="sec14-2042533313518913"><title>Provenance</title><p>Not commissioned; peer-reviewed by George Lewith</p></sec></sec><ref-list><title>References</title><ref id="bibr1-2042533313518913"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Al-Waili</surname><given-names>NS</given-names></name></person-group>
<article-title>Topical application of natural honey, beeswax and olive oil mixture for atopic dermatitis or psoriasis: partially controlled, single-blinded study</article-title>. <source>Complement Ther Med</source>
<year>2003</year>; <volume>11</volume>: <fpage>226</fpage>&#x02013;<lpage>234</lpage><pub-id pub-id-type="pmid">15022655</pub-id></mixed-citation></ref><ref id="bibr2-2042533313518913"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>T</given-names></name><name><surname>Pettersson</surname><given-names>U</given-names></name></person-group>
<article-title>Severe psoriasis &#x02013; oral therapy with a new retinoid</article-title>. <source>Dermatology</source>
<year>1978</year>; <volume>157</volume>: <fpage>238</fpage>&#x02013;<lpage>244</lpage></mixed-citation></ref><ref id="bibr3-2042533313518913"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mason</surname><given-names>AR</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Cork</surname><given-names>M</given-names></name><name><surname>Dooley</surname><given-names>G</given-names></name><name><surname>Hancock</surname><given-names>H</given-names></name></person-group>
<article-title>Topical treatments for chronic plaque psoriasis</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2013</year>; <volume>3</volume>: <fpage>CD005028</fpage>&#x02013;<lpage>CD005028</lpage><pub-id pub-id-type="pmid">23543539</pub-id></mixed-citation></ref><ref id="bibr4-2042533313518913"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Menter</surname><given-names>A</given-names></name><name><surname>Korman</surname><given-names>NJ</given-names></name><name><surname>Elmets</surname><given-names>CA</given-names></name><etal/></person-group>
<article-title>Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies</article-title>. <source>J Am Acad Dermatol</source>
<year>2009</year>; <volume>60</volume>: <fpage>643</fpage>&#x02013;<lpage>659</lpage><pub-id pub-id-type="pmid">19217694</pub-id></mixed-citation></ref></ref-list></back></article>